Reduction of amyloid via amyloid-targeting therapies may result in clinical benefit. 2 key findings →
Design: clinical trial Participants: 1,582 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Research
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
The primary study randomized 272 participants (mean [SD] age, 75.2 [5.5] years; 145 female participants [53.3%]). 3 key findings →
Design: clinical trial Participants: 272 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
76/100
Two hundred eighty-eight patients had paired scans (mean interval 10.9 months). 2 key findings →
Participants: 45 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In this large-scale randomized controlled trial evaluating statin therapy as a treatment for mild to moderate Alzheimer disease, atorvastatin was not associated with significant clinical benefit over 72 weeks. 4 key findings →
Design: randomized controlled trial Participants: 640 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
EGb was safe and appears capable of stabilizing and, in a substantial number of cases, improving the cognitive performance and the social functioning of demented patients for 6 months to 1 year. 5 key findings →
Participants: 309 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Outpatient PC is associated with benefits among patients with PDRD compared with standard care alone. 5 key findings →
Participants: 584 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
p75 neurotrophin receptor (p75 NTR ) signaling pathways substantially overlap with degenerative networks active in Alzheimer disease (AD). 2 key findings →
Participants: 242 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
PDE5I initiation in men with ED was associated with a lower risk of AD, particularly in those most frequently issued prescriptions. 5 key findings →
Design: randomized controlled trial Participants: 269,725 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Observational epidemiological studies have shown a positive association between hypertension and risk of incident dementia; however, the effects of antihypertensive therapy on cognitive function in controlled trials have been conflicting, and meta-analyses of the trials have not provided clear evidence of whether antihypertensive treatment reduces dementia incidence. 5 key findings →
Design: meta-analysis Participants: 1,687 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Occupational therapy improved patients' daily functioning and reduced the burden on the care giver, despite the patients' limited learning ability. 2 key findings →
Design: randomized controlled trial Participants: 135 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Masitinib is an orally administered tyrosine kinase inhibitor that targets activated cells of the neuroimmune system (mast cells and microglia). 4 key findings →
Participants: 182 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Visual speed of processing training delivered on-site or at-home to middle-aged or older adults using standard home computers resulted in stabilization or improvement in several cognitive function tests. 1 key finding →
Participants: 681 Evidence: high
Full summary, score breakdown and related studies → Original source
Alzheimer's dementia (AD) is the sixth leading cause of death in the U.S., with an estimated $305 billion cost of care in 2020. 1 key finding →
Design: randomized controlled trial Participants: 604 Evidence: high
Full summary, score breakdown and related studies → Original source
Multidomain lifestyle interventions represents a promising strategy to counteract cognitive decline in older age. 2 key findings →
Participants: 25 Evidence: high
Full summary, score breakdown and related studies → Original source
A 2-year lifestyle intervention was able to maintain the daily functioning of the at-risk older population. 3 key findings →
Design: randomized controlled trial Participants: 1,260 Evidence: high
Full summary, score breakdown and related studies → Original source
This study indicates that the cognitive and behavioral efficacies of MeMo, a Web-based training app, can be observed only with regular use of the app. 4 key findings →
Participants: 46 Evidence: high
Full summary, score breakdown and related studies → Original source
RS-tDCS is a safe and feasible rehabilitation modality for poststroke cognitive dysfunction. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Cognitive training interventions show to be a potential treatment to ameliorate depression in people with cognitive impairment. 5 key findings →
Participants: 2,551 Evidence: high
Full summary, score breakdown and related studies → Original source
CCT proved effective in PD-MCI patients when compared with traditional PCT. 4 key findings →
Design: randomized controlled trial Participants: 53 Evidence: high
Full summary, score breakdown and related studies → Original source
Combined multi-domain interventions may contribute to preventing or delaying disease progression. 1 key finding →
Design: randomized controlled trial Participants: 33 Evidence: high
Full summary, score breakdown and related studies → Original source
There was no significant difference between the two groups in baseline age, sex, illiteracy, years of education, and scores on the K-MMSE, CDR, SNSB-II, and K-MBI. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
The 2-year multidomain FINGER intervention may modulate white matter microstructural alterations. 2 key findings →
Design: randomized controlled trial Participants: 34 Evidence: high
Full summary, score breakdown and related studies → Original source
There is emerging evidence linking fruit and vegetable consumption and cognitive function. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
76/100
Systematic cognitive training had no effect on global cognition or HRQoL in community-living persons with mild to moderate dementia. 1 key finding →
Design: randomized controlled trial Participants: 147 Evidence: high
Full summary, score breakdown and related studies → Original source
In a large dementia prevention trial with 6-year follow-up, dropout was associated with older age, poorer cognitive function, symptoms of depression, and disability at baseline. 4 key findings →
Design: randomized controlled trial Participants: 2,994 Evidence: high
Full summary, score breakdown and related studies → Original source
From across this tag
10 of the 1,875 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Impact of Training Method on the Robustness of the Visual Assessment of 18F-Florbetaben PET Scans: Results from a Phase-3 Study
- Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab
- Improving Recovery and Outcomes Every Day after the ICU (IMPROVE): study protocol for a randomized controlled trial
- Statins for the prevention of Alzheimer's disease
- Treatment of cognitive impairment after poststroke depression : a double-blind treatment trial
- Bupropion for the Treatment of Apathy in Alzheimer Disease: A Randomized Clinical Trial
- A biobehavioral home-based intervention and the well-being of patients with dementia and their caregivers: the COPE randomized trial
- Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies
- Alzheimer's disease drug development pipeline: 2023
- Triggered Palliative Care for Late-Stage Dementia: A Pilot Randomized Trial
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →